SGLT2 Inhibitors and Adverse Events: A Closer Look
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are an emerging class of medications that have become increasingly popular in medication regimens for diabetic patients [...]
SGLT-2 inhibitor
Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3 CKD
There has been significant interest in SGLT2 inhibitors (SGLT2i) as novel oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes [...]
Sweet Pee: Do SGLT2 Inhibitors Prevent and/or Slow the Progression of Diabetic Kidney Disease?
During NephMadness 2017, the newcomer ‘SGLT2 inhibitors’ team for the Diabetic Nephropathy region surprised the competition and made it all the way to the Filtered Four [...]
#NephMadness 2017: The Year of the Gs – GLP-1 Receptor Agonists and Gonzaga
Submit your picks! | NephMadness 2017 | #NephMadness or #DNRegion Katherine R. Tuttle Dr. Tuttle, MD, is Executive Director for Research at Providence Health Care in [...]